HIMS News & Events

In after-hours trading, shares of Hims & Hers are down 13% to $20.00.

In a post on X.com, HHS General Counsel Mike Stuart wrote, "Based on a review of the applicable facts, earlier today @HHSOGC referred Hims & Hers Health... to the Department of Justice for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

The U.S. Food and Drug Administration announced its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies - including Hims & Hers (HIMS) and other compounding pharmacies - as similar alternatives to FDA-approved drugs. These actions are aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy, the FDA said. The FDA is also taking steps to combat misleading direct-to-consumer advertising and marketing following warning letters that were sent in the fall of 2025. In promotional materials, companies cannot claim that non-FDA-approved compounded products are generic versions or the same as drugs approved by FDA. They also cannot state compounded drugs use the same active ingredient as the FDA-approved drugs or that compounded drugs are clinically proven to produce results for the patient. The FDA will use all available compliance and enforcement tools within its authorities to address unsubstantiated claims and associated public health concerns. Entities engaged in the manufacture, distribution, or marketing of unapproved compounded GLP-1 products should be aware that failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. Publicly traded companies that make GLP-1s include Eli Lilly (LLY) and Novo Nordisk (NVO).

The major averages were sharply higher near noon in a rebound from several days of sharp losses even as Amazon slides. Wall Street appears to be reassessing worries about AI disruption as well as the risks of major investments in the space by big tech.Looking to commodities, gold was on the rise amid continued volatility, while oil prices were also higher.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Amazonreportedand said it expects to invest $200B in capital expenditures in 2026Stellantissaid a reset of its business resulted in, with the company also announcing plans to sell its 49% equity stake in NextStar Energy and the suspension of its annual dividendRedditreportedand provided upbeat Q1 revenue guidanceMolina Healthcarereportedand provided its outlook for FY26Hims & Herswas slipping after FDA commissioner Marty Makary warned againsta day after the company announced a $49 monthly starting price for a copy of Wegovy2. WALL STREET CALLS:Amazonto Neutral from Buy at DA DavidsonFreedom CapitalRobloxto Buy on valuation, better-than-expected outlookRokuto Outperform at OppenheimerGemini Space Stationto In Line at Evercore ISIHub Groupto Sell at Stifel and downgraded to Neutral at Baird3. AROUND THE WEB:AppleCEO Tim Cook told employees an all-hands meeting with staff on Thursday that he's "deeply distraught" with the current U.S. approach to immigration and will continue pressing the issue with lawmakers, Bloomberg reportsSnowboarder Maddie Mastro and other athletes are using a new AI tool powered by GoogleDeepMind's computer vision models to prepare for the 2026 Winter Olympics, WSJ saysTSMCplans to make advanced 3-nanometer chips in Japan, upgrading its original blueprint to produce 7nm chips, Bloomberg reportsHP, Dell, Acer, and Asus are considering sourcing memory chips from Chinese chipmakers, Nikkei Asia saysArm HoldingsCEO Rene Haas believes fears about AI hurting software companies are a "micro-hysteria" that has triggered a market sell-off and exceeds the reality of how businesses are using the tools, FT reports4. MOVERS:SunOptagains after announcing it willfor $6.50 per share in cashStrategyand Billincrease afterGalaxy Digitalincreases after announcing aDoximityfalls afterand announcing its CFO will take a leave of absenceRibbon Communicationsand Impinjlower after5. EARNINGS/GUIDANCEAerCap, with EPS and revenue beating consensusUnder Armourand raised its guidance for FY26Philip Morris, with CEO Jacek Olczak commenting on "another remarkable year of results"Toyota Motorand raised its guidance for FY26Biogen, with EPS and revenue beating consensusINDEXES:Near midday, the Dow was up 1.98%, or 966.95, to 49,875.67, the Nasdaq was up 1.62%, or 365.75, to 22,906.34, and the S&P 500 was up 1.51%, or 102.36, to 6,900.76.